Pharm-Olam International, a multi-national, full-service CRO to the biopharmaceutical and medical device industries, has expanded phase I-IV clinical trial services into the Asia-Pacific region.

This expansion includes the opening of legal entities in Vietnam, Philippines, South Korea, Malaysia, Thailand and Taiwan.

“In response to requests coming in from our clients, we have begun expanding our services into the Asia-Pacific region,” said Sanjiv Suri, Pharm-Olam’s U.S. chief executive officer. “We anticipate significant study growth in the region over the next few years, and we are now poised to guide our clients in the development process in these promising yet often overlooked markets.

“The successes we’ve shared have been a result of offering our clients solutions for their unique needs. Our Asia-Pacific expansion efforts will allow us to offer comprehensive and flexible solutions in a timely and efficient manner. We look forward to continuing to support our clients globally.”